(Q36607415)

15 August 2017

1 reference

title

Treatment of Pseudomonas aeruginosa infection in critically ill patients (English)

1 reference

15 August 2017

main subject

Pseudomonas aeruginosa

object named as

Pseudomonas aeruginosa

1 reference

based on heuristic

inferred from title

author

Daniela Dalla Gasperina

object named as

Daniela Dalla Gasperina

series ordinal

2

0 references

author name string

Paolo Grossi

series ordinal

1

1 reference

15 August 2017

publication date

1 August 2006

1 reference

Expert Review of Anti-infective Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

639-662

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Sepsis in European intensive care units: results of the SOAP study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Five years of nosocomial Gram-negative bacteremia in a general intensive care unit: epidemiology, antimicrobial susceptibility patterns, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Nosocomial infections caused by multiresistant Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Pseudomonas: global bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Emergence of resistance in Pseudomonas aeruginosa and Acinetobacter species after the use of antimicrobials for burned patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: the RADAR-trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Pseudomonas aeruginosa AmpR is a global transcriptional factor that regulates expression of AmpC and PoxB beta-lactamases, proteases, quorum sensing, and other virulence factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

A functional classification scheme for beta-lactamases and its correlation with molecular structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

An integron-associated beta-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum beta-lactamase IBC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Metallo-beta-lactamases: a class apart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Emerging carbapenemases in Gram-negative aerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Nosocomial infections caused by multidrug-resistant isolates of pseudomonas putida producing VIM-1 metallo-beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

21 January 2018

The new beta-lactamases.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Metallo-beta-lactamases: the quiet before the storm?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Aminoglycoside resistance in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Aminoglycoside antibiotic resistance by enzymatic deactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Function of pseudomonas porins in uptake and efflux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Efflux-mediated multiresistance in Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Structure of the periplasmic component of a bacterial drug efflux pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antimicrobial resistance of Pseudomonas aeruginosa biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Prescribing guidelines for severe Pseudomonas infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Prevalence and characterization of metallo-beta-lactamases in clinical isolates of pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

A pilot study of antibiotic cycling in a hematology-oncology unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Animal model pharmacokinetics and pharmacodynamics: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Pharmacodynamics of cefepime in patients with Gram-negative infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Experience with a clinical guideline for the treatment of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Science and pragmatism in the treatment and prevention of neutropenic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Efficacy of rifampicin in experimental Bacteroides fragilis and Pseudomonas aeruginosa mixed infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Gentamicin dosing in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Hospital-based strategies for combating resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Carbapenems in serious infections: a risk-benefit assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Duration of empiric antibiotic therapy in granulocytopenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Changes in strategies for optimal antibacterial therapy in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

New antimicrobials in the management of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Infections of the central nervous system due to pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Cefepime in the empiric treatment of meningitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Efficiency of cefepime in postoperative meningitis attributable to Enterobacter aerogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Practice guidelines for the management of bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Ciprofloxacin in the treatment of gram-negative bacillary meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Intrathecal amikacin for the treatment of pseudomonal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Aztreonam for treating meningitis caused by gram-negative rods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis. Case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

The rational use of antibiotics in the treatment of brain abscess

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Pseudomonas aeruginosa infective endocarditis presenting as bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Evolving trends in infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

21 January 2018

Infective endocarditis.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Current best practices and guidelines indications for surgical intervention in infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Intensive care unit-acquired urinary tract infections in a regional critical care system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Overview of nosocomial infections caused by gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care u

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Pharmacologic and toxicologic studies with the polymyxins. 3. Consideration regarding clinical use in dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Neurotoxic and nephrotoxic effects of colistin in patients with renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Colistin: an antimicrobial for the 21st century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

The rationale for aerosolized antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar typhimurium intracellular infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Enhanced liposome-mediated antibacterial activity of piperacillin and gentamicin against gram-negative bacilli in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. infections: the state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

In vitro antimicrobial activity of doripenem, a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Activities of doripenem (S-4661) against drug-resistant clinical pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Inhibitors of efflux pumps in Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Quorum-sensing inhibitors as anti-pathogenic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Identity and effects of quorum-sensing inhibitors produced by Penicillium species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

Pseudomonas aeruginosa: in vitro susceptibility to antimicrobial drugs, single and combined, with and without defibrinated human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.639

21 January 2018

Identifiers

DOI

10.1586/14787210.4.4.639

1 reference

15 August 2017

1 reference